Antibodies targeting glioblastoma stem-like cells and methods of use thereof
US-2024018263-A1 · Jan 18, 2024 · US
Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
US9694061B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9694061-B2 |
| Application number | US-201514887700-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 20, 2015 |
| Priority date | Oct 16, 2008 |
| Publication date | Jul 4, 2017 |
| Grant date | Jul 4, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed herein are isolated human monoclonal antibodies, and functional fragments thereof, that specifically bind HMW-MAA. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect HMW-MAA in a sample. Methods of diagnosing cancer, or confirming a diagnosis of cancer, are disclosed herein that utilize these antibodies. Methods of treating a subject with cancer are also disclosed.
First claim
Opening claim text (preview).
The invention claimed is: 1. An isolated nucleic acid molecule encoding a HMW-MAA-specific monoclonal antibody or antigen-binding fragment thereof, wherein the heavy chain variable region of the antibody or antigen-binding fragment thereof comprises amino acids 27-38, 56-55 and 105-115 of SEQ ID NO: 5, and the light chain variable region of the antibody or antigen-binding fragment thereof comprises amino acids 27-38, 56-65 and 105-110 of SEQ ID NO: 6. 2. The isolated nucleic acid molecule of claim 1 , wherein the heavy chain variable region of the antibody or antigen-binding fragment thereof comprises SEQ ID NO: 5. 3. The isolated nucleic acid molecule of claim 1 , wherein the light chain variable region of the antibody or antigen-binding fragment thereof comprises SEQ ID NO: 6. 4. The isolated nucleic acid molecule of claim 1 , wherein the heavy chain variable region of the antibody or antigen-binding fragment thereof comprises SEQ ID NO: 5, and the light chain variable region of the antibody or antigen-binding fragment thereof comprises SEQ ID NO: 6. 5. The isolated nucleic acid molecule of claim 1 operably linked to a promoter. 6. An expression vector comprising the isolated nucleic acid molecule of claim 1 . 7. An isolated host cell transformed with the expression vector of claim 6 . 8. An isolated host cell transformed with the nucleic acid molecule of claim 1 .
Assignees
Inventors
Classifications
variable (Fv) region, i.e. VH and/or VL · CPC title
from primates, e.g. man · CPC title
specific for leukemia · CPC title
Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation · CPC title
from tumour cells · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9694061B2 cover?
- Disclosed herein are isolated human monoclonal antibodies, and functional fragments thereof, that specifically bind HMW-MAA. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect HMW-MAA in a sample. Methods of diagnosing cancer, …
- Who is the assignee on this patent?
- Univ Of Pittsburgh—Of The Commonwealth System Of Higher Education
- What technology area does this patent fall under?
- Primary CPC classification C07K16/3053. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).